Fast Prototyping for Video Monitoring Systems with the Use of DSP Module

This paper presents techniques for fast prototyping of real-time hardware / software video processing systems for urban surveillance monitoring equipment. During the experimental research the evaluation module with the TMS320DM6437 signal processor programmed with the use of the Code Composer Studio and Matlab / Simulink environments has been used. Analyzed algorithms can support the work of monitoring video operators. In particular, we analyzed efficiency of implementation of the algorithms using two examples: detection of painting theft and signaling of crossing a pedestrian pass at the red light

Synthesis of new 4-butyl-arylpiperazine-3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives and evaluation for their 5-HT1A_{1A} and D2_{2} receptor affinity and serotonin transporter inhibition

A series of novel 4-butyl-arylpiperazine-3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives were synthesized and evaluated for their 5-HT$_{1A}$/D2 receptor affinity and serotonin reuptake inhibition. The compounds exhibited high affinity for the 5-HT$_{1A}$ receptor, (especially 4d K$_{i}$ = 0.4 nM) which depended on the substitution pattern at the phenylpiperazine moiety. From this series screen, compound 4c emerged with promising mixed receptor profiles for the 5-HT$_{1A}$/D2 receptors and the serotonin transporter (K$_{i}$ = 1.3 nM, 182 nM and 64 nM, respectively).long-chain arylpiperazinesdepression5-HT$_{1A}$ receptor ligandsschizophreniamulti-target ligand

Zmienność dobowa w układzie hemostazy

Rytmy biologiczne to uniwersalne zjawisko występujące u żywych organizmów. Biorą one udział w adaptacji organizmu do otoczenia i polegają na synchronizacji własnych procesów życiowych z regularnymi zjawiskami występującymi w otaczającym środowisku. Reaktywność naczyń krwionośnych w dużej mierze zależy od prawidłowej funkcji śródbłonka naczyniowego, na którą istotnie wpływają rytmy biologiczne. Podobną wyraźną zależność między rytmami biologicznymi i hemostazą obserwuje się nie tylko w badaniach doświadczalnych, lecz także klinicznych. Okołotygodniowy rytm w układzie hemostazy, łącznie z 7-dniowymi zmianami w otaczającym środowisku (aktywność, stres, dieta), prowadzą do zwiększonego ryzyka incydentów sercowo-naczyniowych, zwłaszcza na początku tygodnia. Zjawiska te są ściśle skorelowane z rytmami okołodobowymi w układzie hemostazy. Poranny wzrost lepkości krwi, napięcia mięśniówki naczyń, odpowiedzi na działanie norepinefryny, ciśnienia krwi, aktywności płytek i krzepliwości krwi wraz ze zmniejszaną aktywnością fibrynolityczną prowadzą do zwiększonego ryzyka zdarzeń zakrzepowo-zatorowych w tym czasie. Zmiany te ułatwiają zrozumienie epidemiologicznych obserwacji wzmożonego występowania incydentów zakrzepowych w godzinach porannych i na początku tygodnia. Folia Cardiologica Excerpta 2010; 5, 1: 1-

Pre-hospital management of penetrating pelvic injuries — a case study

INTRODUCTION: Penetrating pelvic injuries and the complications caused by them are a global problem in the provision of services by emergency medical teams. They often pose a significant challenge for medical personnel, particularly in patient evacuation and stabilization during transport. CASE REPORT: The emergency medical service (EMS) was dispatched to a traffic accident — the report contained information about one conscious victim with a foreign body within the patient's body. At the accident scene, a delivery truck crashed into the tow bar of a trailer standing on the road, and one person was seriously injured due to the impact. The preliminary assessment confirmed a foreign body penetrating the right thigh, deformation and enlargement of the thigh contour, pain in the thigh, pelvis, and tenderness in the thoracic-lumbar spine with the end part of the tow bar hook palpable under the skin. The victim was suspected of having a femur fracture, pelvic injuries, and damage to internal organs. On neurological examination, sensation and motor functions were preserved in all limbs. The evacuation procedure was established after the Fire Department (FD) rescuers arrived. The injured person was removed from the vehicle on an orthopedic board with the help of eight rescuers. The victim was placed on his left side with the right side elevated, with continuous manual stabilization supported by a blanket, pillows, and orthopedic boar straps. CONCLUSIONS: Each traumatic injury event requires selecting and using the appropriate equipment. A good compromise between speed and precision of actions should not significantly contribute to the worsening of the injury. An increase in a rescuer's substantive knowledge on how to proceed in the case of this type of trauma and injuries, as well as close cooperation with the fire department, will undoubtedly result in more appropriate actions

Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome

Background: Antiplatelet therapy has proven beneficial in the treatment of cardiovascular disease. Proton pump inhibitors (PPIs) are commonly used for gastroprotection in patients receiving antiplatelet therapy. Several trials have been carried out to establish interactions between PPIs, clopidogrel and soluble formulations of aspirin, but no studies with PPIs and enteric-coated (EC) forms of aspirin have been conducted. The aim of this study was to assess if concomitant pantoprazole usage influences antiplatelet effect of EC aspirin in patients with acute coronary syndrome treated with percutaneous coronary intervention (PCI) and dual antiplatelet therapy. Methods: Thirty-one consecutive patients were prospectively enrolled in the randomized, crossover, open-labelled designed study. The first 16 patients were given orally 40 mg of pantoprazole for the first four days while the next 15 subjects were treated with pantoprazole from the fifth to the eighth day of hospitalisation. Blood samples were collected at 6.00 a.m., 10.00 a.m., 2.00 p.m., and 7.00 p.m. on the fourth and eighth day of hospitalization. Aggregation in response to arachidonic acid was assessed in the whole blood on a new generation impedance aggregometer. Results: Lower overall platelet aggregation in patients treated with pantoprazole (p < 0.03) was observed. When aggregation of platelets was analyzed separately at different times, the differences reached statistical significance six hours after the administration of pantoprazole and antiplatelet agents. The highest absolute difference in arachidonic acid-dependent aggregation was observed two hours after drug ingestion. Conclusions: Co-administration of pantoprazole may enhance the antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome undergoing PCI

The COVID-19 drive-through point — screening and testing — first in Poland complex centre experience

Introduction: Rapid widespread of the SARS-CoV-2 virus in early 2020 caused global chaos. In the initial period, a lack of knowledge of epidemiology and viral contamination, as well as no availability of either causal treatment or preventive vaccination, resulted in mass testing of symptomatic individuals as the priority for protection. This study aimed to evaluate the effectiveness and safety of the first COVID-19 (coronavirus disease) drive-through testing model in the Greater Poland Region. Material and methods: The authors demonstrate step-by-step the creation and development of the Centre of Medical Simulation Poznan University of Medical Sciences (PUMS) COVID-19 drive-through testing point for 3.5 million inhabitants in the Greater Poland Region during the 1st through 4th coronavirus pandemic waves. For staff education, low and high-fidelity simulation techniques were used. Additionally, the number of tests performed at the swab point and the efficiency of the developed testing model were evaluated and assessed in all pandemic waves. Results: PUMS POST (point of screening and testing) activity lasted 24 months. Improvement of staff skills developed through simulation training increased the median number of 91 patients tested each day (with a median of 25 tests per hour) during the 1st wave to a maximum of 260 patients tested each day (135 tests per hour) during the 4th wave when the new drive-through POST system was employed (p &lt; 0.001). Conclusion: The present study supported the previous preliminary reports that drive-through systems developed during the COVID-19 pandemic proved to be efficient and safe for mass population testing. Moreover, the Medical Simulation Centre confirmed the effectiveness of staff skills improvement

Diurnal variation in platelet inhibition by clopidogrel

Morning increase in the occurrence of myocardial infarction, stroke and sudden cardiac death is a well-recognized phenomenon, which is in line with a morning enhancement of platelet aggregation. We investigated whether platelet inhibition during clopidogrel and aspirin therapy varies during the day. Fifty-nine consecutive patients (45 men and 14 women) with first ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary interventions (pPCI) on dual antiplatelet therapy were prospectively enrolled into the study. Blood samples were collected 4 days after start of clopidogrel treatment at 6.00 a.m., 10.00 a.m., 2.00 p.m. and 7.00 p.m. Arachidonic acid and adenosine diphosphate (ADP)-induced platelet aggregation were assessed by impedance aggregometry. Platelet inhibition by clopidogrel was lowest in the midmorning: median ADP-induced platelet aggregation was 55%, 17% and 27% higher at 10.00 a.m. compared to 6.00 a.m., 2.00 p.m. and 7.00 p.m., respectively ( p<0.002). Nonresponsiveness to clopidogrel defined according to the device manufacturer was 2.4-fold more frequent in the midmorning than in the early morning. We observed a more pronounced midmorning increase in ADP-induced platelet aggregation in diabetic patients when compared to non-diabetics. In contrast, no diurnal variation in the antiplatelet effect of aspirin was observed. In conclusion, in patients presenting with STEMI undergoing pPCI, platelet inhibition by clopidogrel is less strong in the midmorning hours. This periodicity in platelet aggregation in patients on dual antiplatelet therapy should be taken into consideration when assessing platelet function in clinical studies

Enhanced antiplatelet effect of enteric- -coated acetylsalicylic acid in co-administration with pantoprazole

Background. Proton pump inhibitors (PPI) are recommended for patients receiving antiplatelet therapy. Several studies have revealed that PPI may attenuate the antiplatelet effect of ASA. However, our pilot study has indicated a positive interaction between pantoprazole and enteric-coated aspirin. The aim of the current study was to confirm that pantoprazole enhances the antiplatelet effect ofenteric-coated aspirin in patients with acute coronary syndrome (ACS) treated with dual antiplatelettherapy. Moreover, the influence of CYP2C19 polymorphism on the antiplatelet effect of aspirinwas assessed.Material and methods. Ninety three consecutive ACS patients were prospectively enrolled in a randomized, crossover, open-labeled study. Forty four patients were given orally 40 mg of pantoprazole for the initial fourdays while the remaining forty nine were treated with pantoprazole from the 5th to the 8th day of hospitalization. Blood samples were collected at 6.00 a.m., 10.00 a.m., 2.00 p.m., and 7.00 p.m. on the 4th and 8th daysof hospitalization. Aggregation in response to arachidonic acid was assessed by impedance aggregometry.Results. Lower mean platelet aggregation on pantoprazole was observed on the 8th day of hospitalization(p = 0.03). A cross-time analysis of platelet aggregation demonstrated statistical significance at two hoursand six hours after co-administration of pantoprazole and antiplatelet agents, with the highest absolutedifference observed two hours after drugs ingestion. No significant differences in aggregation betweenstudy groups were observed on the 4th day of hospitalization. No influence of CYP2C19 polymorphismon the antiplatelet effect of aspirin was observed.Conclusions. Co-administration of pantoprazole enhances the antiplatelet effect of enteric-coated aspirinin patients with ACS.Background. Proton pump inhibitors (PPI) are recommended for patients receiving antiplatelet therapy.Several studies have revealed that PPI may attenuate the antiplatelet effect of ASA. However, our pilot study has indicated a positive interaction between pantoprazole and enteric-coated aspirin.The aim of the current study was to confirm that pantoprazole enhances the antiplatelet effect ofenteric-coated aspirin in patients with acute coronary syndrome (ACS) treated with dual antiplatelettherapy. Moreover, the influence of CYP2C19 polymorphism on the antiplatelet effect of aspirinwas assessed.Material and methods. Ninety three consecutive ACS patients were prospectively enrolled in a randomized, crossover, open-labeled study. Forty four patients were given orally 40 mg of pantoprazole for the initial fourdays while the remaining forty nine were treated with pantoprazole from the 5th to the 8th day of hospitalization. Blood samples were collected at 6.00 a.m., 10.00 a.m., 2.00 p.m., and 7.00 p.m. on the 4th and 8th daysof hospitalization. Aggregation in response to arachidonic acid was assessed by impedance aggregometry.Results. Lower mean platelet aggregation on pantoprazole was observed on the 8th day of hospitalization(p = 0.03). A cross-time analysis of platelet aggregation demonstrated statistical significance at two hoursand six hours after co-administration of pantoprazole and antiplatelet agents, with the highest absolutedifference observed two hours after drugs ingestion. No significant differences in aggregation betweenstudy groups were observed on the 4th day of hospitalization. No influence of CYP2C19 polymorphismon the antiplatelet effect of aspirin was observed.Conclusions. Co-administration of pantoprazole enhances the antiplatelet effect of enteric-coated aspirinin patients with ACS

Erotetic Reasoning Corpus. A data set for research on natural question processing

The aim of this paper is to present the Erotetic Reasoning Corpus (ERC) which constitutes a data set for research on natural question processing. We describe the theoretical background, linguistic data and tags used for the annotation process. We also discuss potential areas of ERC exploitation